NASDAQ Framework: STAAR Surgical Company
1: STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. View Source2: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment. View Source
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye and companion delivery systems to deliver the lenses into the eye 3. The company offers two primary products: Implantable Collamer lenses (ICLs) used in refractive surgery and intraocular lenses (IOLs) used in cataract surgery 4. STAAR Surgical markets its products to healthcare providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, and operates both directly and through independent distributors in various international markets 5. The company was incorporated in 1982 and is headquartered in Lake Forest, California 6.
3: STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. View Source4: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment. View Source5: STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. View Source6: STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. View Source
UNKNOWN
The provided facts do not contain information about whether STAAR Surgical Company is still led by its founders or if the founders are heavily involved in the company's operations.
The provided facts do not contain information about whether STAAR Surgical Company is still led by its founders or if the founders are heavily involved in the company's operations.
MEDIUM RISK
STAAR Surgical Company exhibits both strengths and weaknesses in its financial situation. On the positive side, the company has demonstrated revenue growth of approximately 5.21% as of March 31, 2024 7, and maintains a low debt-to-equity ratio of 0.09, indicating a healthier balance between debt and equity 8. However, the company also reported a net margin of -4.32% 9 and a return on assets (ROA) of -0.68% 10, both of which are negative and suggest challenges in profitability and asset utilization. Additionally, the company missed earnings expectations in Q1 2024, reporting a net loss 1112. These mixed indicators place STAAR Surgical in a borderline financial situation, warranting a medium risk assessment.
STAAR Surgical Company exhibits both strengths and weaknesses in its financial situation. On the positive side, the company has demonstrated revenue growth of approximately 5.21% as of March 31, 2024 7, and maintains a low debt-to-equity ratio of 0.09, indicating a healthier balance between debt and equity 8. However, the company also reported a net margin of -4.32% 9 and a return on assets (ROA) of -0.68% 10, both of which are negative and suggest challenges in profitability and asset utilization. Additionally, the company missed earnings expectations in Q1 2024, reporting a net loss 1112. These mixed indicators place STAAR Surgical in a borderline financial situation, warranting a medium risk assessment.
7: Revenue Growth: Staar Surgical displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 5.21%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector. View Source8: Debt Management: Staar Surgical's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors. View Source9: Net Margin: Staar Surgical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.32%, the company showcases strong profitability and effective cost management. View Source10: Return on Assets (ROA): Staar Surgical's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.68% ROA, the company effectively utilizes its assets for optimal returns. View Source11: STAAR Surgical Company (NASDAQ:STAA) Q1 2024 Earnings Call Transcript View Source12: Staar Surgical Co Reports Q1 2024 Results: Misses Earnings Projections Despite Revenue Growth View Source
NO
The provided facts do not contain information about STAAR Surgical Company launching any new product offerings.
The provided facts do not contain information about STAAR Surgical Company launching any new product offerings.
STAAR Surgical Company's product roadmap and expansion strategy for 2024 through to 2026 focuses on strengthening its market presence and advancing its product offerings. The company has recently announced a milestone strategic agreement in the U.S. with IQ Laser Vision, which is expected to enhance its distribution network and market reach 13. Additionally, STAAR Surgical is actively participating in significant industry conferences, such as the Goldman Sachs 45th Annual Global Healthcare Conference, to engage with investors and stakeholders 1415. The company is also making strategic leadership appointments, including the addition of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel, to bolster its management team and drive future growth 1617. These initiatives indicate STAAR Surgical's commitment to expanding its footprint and enhancing its product portfolio in the ophthalmic surgical market.
13: STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision View Source14: Investor's Business Daily•27 days agoStaar Surgical Stock Earns RS Rating UpgradeStaar Surgical shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 87.Zacks•27 days agoStaar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock?Staar Surgical (STAA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.Business Wire•2 months agoSTAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare ConferenceLAKE FOREST, Calif., June 05, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, which will be held in Miami, Florida.Simply Wall St.•2 months agoIs It Time To Consider Buying STAAR Surgical Company (NASDAQ:STAA)?STAAR Surgical Company ( NASDAQ:STAA ), is not the largest company out there, but it received a lot of attention from a...Zacks•2 months agoDon't Overlook Staar Surgical (STAA) International Revenue Trends While Assessing the StockReview Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.Simply Wall St.•2 months agoSTAAR Surgical First Quarter 2024 Earnings: Beats ExpectationsSTAAR Surgical ( NASDAQ:STAA ) First Quarter 2024 Results Key Financial Results Revenue: US$77.4m (up 5.2% from 1Q...Insider Monkey•3 months agoSTAAR Surgical Company (NASDAQ:STAA) Q1 2024 Earnings Call TranscriptSTAAR Surgical Company (NASDAQ:STAA) Q1 2024 Earnings Call Transcript May 7, 2024 STAAR Surgical Company misses on earnings expectations. Reported EPS is $-0.06827 EPS, expectations were $0.05. STAAR Surgical Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome […]GuruFocus.com•3 months agoStaar Surgical Co (STAA) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amid ...Despite a net loss, STAAR Surgical reports robust sales growth and strategic advancements in key markets.Zacks•3 months agoStaar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to SayThe headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.GuruFocus.com•3 months agoStaar Surgical Co Reports Q1 2024 Results: Misses Earnings Projections Despite Revenue GrowthChallenging Economic Conditions Impact Profitability Amidst Revenue Increase View Source15: STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference View Source16: These small-cap stocks score highest when screened for quality MarketWatch Jul 20, 2024 10:56am These small-cap stocks score highest when -2- MarketWatch Jul 20, 2024 10:56am STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference Business Wire Jun 5, 2024 11:00am STAAR Surgical Reports First Quarter 2024 Results Business Wire May 7, 2024 8:03pm STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision Business Wire May 7, 2024 8:01pm STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel Business Wire May 1, 2024 11:00am STAAR Surgical to Report First Quarter Results on May 7, 2024 Business Wire Apr 29, 2024 11:00am Dolby stock rises on upcoming move to S&P MidCap 400 MarketWatch Aug 17, 2023 9:46pm View Source17: These small-cap stocks score highest when screened for quality MarketWatch Jul 20, 2024 10:56am These small-cap stocks score highest when -2- MarketWatch Jul 20, 2024 10:56am STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference Business Wire Jun 5, 2024 11:00am STAAR Surgical Reports First Quarter 2024 Results Business Wire May 7, 2024 8:03pm STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision Business Wire May 7, 2024 8:01pm STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel Business Wire May 1, 2024 11:00am STAAR Surgical to Report First Quarter Results on May 7, 2024 Business Wire Apr 29, 2024 11:00am Dolby stock rises on upcoming move to S&P MidCap 400 MarketWatch Aug 17, 2023 9:46pm View Source